TODAY’S NEWS
Big news for Novartis on two fronts – Novartis has received a couple of pieces of good news from regulators in the USA this morning who have approved its meningococcal vaccine Menveo and granted a priority review for the Swiss major’s investigational oral treatment for multiple sclerosis fingolimod…more
Avandia – the bad news just won’t quit. The heart attack factor, and the when-did-they-not-share-what-info questions. And a call to just pull it from the market. A rough patch for GSK.
BI gets FDA approval for new Extended Release version of Mirapex (for Parkinson’s)
RECOMMENDED
Specialty sales training – For specialty sales forces (including oncology), you need specialized expertise. We have lots of it, in our Impactiviti Partner network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for vendor recommendations.
PLUS
From Wendy Blackburn: 7 things I Learned at the ePharma Summit. And, from Betsy Raymond Stevenson – Curing Pharma. Restoring the industry’s reputation will mean a lot of hard work, not just a PR campaign.
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
Impactiviti blog 